Balyasny Asset Management
ACAD icon

Balyasny Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Balyasny Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.82M Buy
388,024
+75,042
+24% +$1.65M 0.01% 1063
2026
Q1 		$6.97M Buy
+312,982
New +$7.48M 0.01% 1206
2025
Q1 		– Sell
-396,922
Closed -$7.21M – 2731
2024
Q4 		$7.28M Sell
396,922
-727,650
-65% -$11.7M 0.01% 1105
2024
Q3 		$17.3M Buy
1,124,572
+352,426
+46% +$5.88M 0.03% 705
2024
Q2 		$12.5M Buy
+772,146
New +$12.5M 0.02% 785
2024
Q1 		– Sell
-300,875
Closed -$9.42M – 2558
2023
Q4 		$9.42M Buy
300,875
+284,557
+1,744% +$6.8M 0.02% 891
2023
Q3 		$340K Buy
+16,318
New +$443K ﹤0.01% 1867
2023
Q1 		– Sell
-2,578
Closed -$41K – 2577
2022
Q4 		$41K Buy
+2,578
New +$40.3K ﹤0.01% 2374
2022
Q3 		– Sell
-10,390
Closed -$146K – 2805
2022
Q2 		$146K Buy
+10,390
New +$194K ﹤0.01% 2236
2022
Q1 		– Sell
-85,687
Closed -$2M – 2427
2021
Q4 		$2M Sell
85,687
-43,291
-34% -$871K 0.01% 1212
2021
Q3 		$2.14M Buy
+128,978
New +$2.49M 0.01% 1103
2020
Q4 		– Sell
-67,864
Closed -$2.8M – 1269
2020
Q3 		$2.8M Buy
67,864
+60,072
+771% +$2.59M 0.02% 752
2020
Q2 		$378K Buy
+7,792
New +$374K ﹤0.01% 965
2019
Q1 		– Sell
-78,845
Closed -$1.27M – 1368
2018
Q4 		$1.27M Sell
78,845
-1,177,231
-94% -$22.9M 0.01% 830
2018
Q3 		$26.1M Buy
1,256,076
+1,173,483
+1,421% +$18.5M 0.12% 240
2018
Q2 		$1.26M Buy
+82,593
New +$1.47M 0.01% 1067
2018
Q1 		– Sell
-357,958
Closed -$9.91M – 1891
2017
Q4 		$10.8M Buy
+357,958
New +$11.4M 0.03% 614
2017
Q3 		– Sell
-141,745
Closed -$3.95M – 1837
2017
Q2 		$3.95M Buy
+141,745
New +$4.22M 0.02% 806
2017
Q1 		– Sell
-432,691
Closed -$12.5M – 1560
2016
Q4 		$12.5M Buy
+432,691
New +$11.4M 0.07% 414

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management's ACAD Position: Q2 2026 in Review

Balyasny Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 24% in Q2 2026, buying an estimated $1.65M and bringing the position to 388,024 shares worth $9.82M. The position accounts for 0.01% of the portfolio, ranked #1063.

Balyasny Asset Management first reported a position in ACAD in Q4 2016 and has held it in 19 quarters since. The position peaked at $26.1M in Q3 2018. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Balyasny Asset Management held 388,024 shares of Acadia Pharmaceuticals worth $9.82M as of Q2 2026.
  • Balyasny Asset Management bought 75,042 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Acadia Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1063 holding.
  • Balyasny Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
  • Balyasny Asset Management's Acadia Pharmaceuticals position peaked at $26.1M in Q3 2018.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.